Evidence Hub

Interleukin-17 as predictor mortality of septic patients: a systematic review and meta-analysis

Dwi Retnoningrum, Budi Eko Mulyono, Umi Solekhah Intansari, Ardhea Jaludamascena

Wiadomości Lekarskie, 2024

194 participants · 3 citations

Abstract

OBJECTIVE: Aim: This study aimed to prove the role of IL-17 on the clinical outcomes of septic patients. PATIENTS AND METHODS: Materials and Methods: This study used a systematic review and meta-analysis design. Data were obtained by searching articles published between January 2001 and June 2022 in Pubmed, Science Direct, Scopus, and Medline databases to evaluate Interleukin-17 on clinical outcomes in septic patients. Only human studies were used in this study. Meta-analysis was undertaken using random effects models. RESULTS: Results: Fourteen published studies were eligible, and four studies were included in the meta-analysis. Meta-analysis of the ratio of means (RoM) IL-17 concentration demonstrated a 5.96-fold higher level in non-survivor septic patients compared with survivors (four studies; n = 194 patients; RoM=5.96; 95% CI, 3.51-10.31; p < 0.00001; I2 = 92%). CONCLUSION: Conclusions: IL-17 levels were significantly elevated in non-survivor and predicted mortality of septic patients.

How strong is the evidence?

Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 194 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free